Hepatic mosaic enhancement pattern correlates with increased inflammatory activity and adverse therapeutic outcomes in patients with Crohn’s disease
- 1 March 2021
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 46 (7) , 3149-3158
Abstract
Purpose This study aimed to evaluate the role of hepatic mosaic enhancement pattern (HMEP) on computed tomography images in the disease activity and therapeutic outcome of Crohn’s Disease (CD). Methods Twenty-five CD patients with HMEP comprised the HMEP group, and 25 CD patients without HMEP, who had a similar onset age, sex, and disease course with those in the HMEP group, comprised the non-HMEP group. No underlying liver/biliary disease was observed in any of the patients. Clinical characteristics, laboratory test results, Lémann index, and CD endoscopic index of severity (CDEIS) were compared between the groups using the Student t-, Mann–Whitney U, Chi square, or Fisher’s exact tests. Patients received top-down, step-up, or traditional treatment during the follow-up period. After the 1-year follow-up, therapeutic outcomes (active inflammation [CDEIS > 3.5 if the endoscopic data were available, or C-reactive protein level > 5 mg/L if the endoscopic data were unavailable] or remission) were evaluated. Results The occurrence rate of fistulas/abscesses was higher in the HMEP group (84%, 21/25) than in the non-HMEP group (48%, 12/25) with no statistical significance (P = 0.056). The HMEP group showed a higher C-reactive protein level (P = 0.001), erythrocyte sedimentation rate (P = 0.013), and blood platelet count (P = 0.005). There was no significant difference in therapeutic strategies between the groups (P = 0.509). The HMEP group showed a significantly lower remission ratio after anti-inflammatory treatment than the non-HMEP group (P = 0.045). Conclusions HMEP was correlated with increased inflammatory activity and adverse therapeutic outcomes in CD. This finding provided insights regarding novel markers of CD diagnosis and treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81870451, 81600508, 81770654, 82072002, 82070680, 81971684, 81771908)
- National Natural Science Foundation of China (81870451, 81600508, 81770654, 82072002, 82070680, 81971684, 81771908)
This publication has 36 references indexed in Scilit:
- Development of the Crohnʼs disease digestive damage score, the Lémann scoreInflammatory Bowel Diseases, 2011
- Platelets, inflammation and tissue regenerationThrombosis and Haemostasis, 2011
- Gut-Liver Axis and Sensing MicrobesDigestive Diseases, 2010
- Matrix metalloproteinase 9 is involved in Crohn’s disease-associated platelet hyperactivation through the release of soluble CD40 ligandGut, 2008
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Platelet-Derived Serotonin Mediates Liver RegenerationScience, 2006
- CD4+ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and plateletsHepatology, 2006
- Imaging Findings of Hepatic Sinusoidal DilatationAmerican Journal of Roentgenology, 2004
- Significance of systemic endotoxaemia in inflammatory bowel disease.Gut, 1995
- Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent plateletsNature, 1992